Statins Do not decrease the risk for Wet age-related macular degeneration

Current Eye Research

Volumn 34, Issue 4, 2009, Pages 304-310

  Kaiserman, Nadia ^a,f   Vinker, Shlomo ^b,c   Kaiserman, Igor ^d,e  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b CLALIT HEALTH SERVICES   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d BARZILAI MEDICAL CENTER   (Israel)

^e BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^f NONE   (Israel)

Author keywords

Age related macular degeneration; Atherosclerosis; Choroidal neovascularization; Photodynamic therapy; Statins

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; BIRTHPLACE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; FEMALE; GROUPS BY AGE; HEALTH MAINTENANCE ORGANIZATION; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; ISRAEL; MAJOR CLINICAL STUDY; MALE; PHOTODYNAMIC THERAPY; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RESIDENTIAL HOME; RETINA MACULA AGE RELATED DEGENERATION; RISK FACTOR; SEX DIFFERENCE; SOCIAL STATUS; AGED; CASE CONTROL STUDY; MIDDLE AGED; PHOTOCHEMOTHERAPY; RETINA MACULA DEGENERATION; RISK; RISK ASSESSMENT; STATISTICS;

AGED; CASE-CONTROL STUDIES; DRUG PRESCRIPTIONS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MACULAR DEGENERATION; MALE; MIDDLE AGED; ODDS RATIO; PHOTOCHEMOTHERAPY; RISK ASSESSMENT;

EID: 67649643741     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.1080/02713680902741670     Document Type: Article

References (38)

1. Klein R, Klein BE, Jensen SC. The relation of cardiovascular disease and its risk factors to the 5-year incidence of agerelated maculopathy: The Beaver Dam Eye Study. Ophthalmology. 1997;104:1804-1812.
2. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology. 1992;99:933-943.
3. Leibowitz HM, Krueger DE, Maunder LR, et al. The Framingham Eye Study monograph: An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. Surv Ophthalmol. 1980;24:335-610.
4. Klein R, Klein BE, Jensen SC, et al. Medication use and the 5-year incidence of early age-related maculopathy: The Beaver Dam Eye Study. Arch Ophthalmol. 2001;119:1354-1359.
5. van Leeuwen R, Ikram MK, Vingerling JR, Witteman JC, Hofman A, de Jong PT. Blood pressure, atherosclerosis, and the incidence of age-related maculopathy: The Rotterdam Study. Invest Ophthalmol Vis Sci. 2003;44:3771-3777.
6. Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report No. 3. Ophthalmology. 2000;107:2224-2232.
7. Hyman L, Schachat AP,HeQ,Leske MC. Hypertension, cardiovascular disease, and age-related macular degeneration. Age-Related Macular Degeneration Risk Factors Study Group. Arch Ophthalmol. 2000;118:351-358.
8. Kaiserman I, Kaiserman N, Elhayany A, Vinker S. Risk factors for photodynamic therapy of predominantly classic choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol. 2006;142:441-447.
9. Clemons TE, Milton RC, Klein R, Seddon JM, Ferris III FL. Risk factors for the incidence of advanced age-related macular degeneration in the Age-Related Eye Disease Study (AREDS)- AREDS Report No. 19. Ophthalmology. 2005;112:533-539.
10. McCarty CA, Mukesh BN, Fu CL, Mitchell P, Wang JJ, Taylor HR. Risk factors for age-related maculopathy: The Visual Impairment Project. Arch Ophthalmol. 2001;119:1455-1462.
11. Schaumberg DA, Christen WG, Hankinson SE, Glynn RJ. Body mass index and the incidence of visually significant age-related maculopathy in men. Arch Ophthalmol. 2001;119:1259-1265.
12. Cruickshanks KJ, Klein R, Klein BE, Nondahl DM. Sunlight and the 5-year incidence of early age-related maculopathy: The Beaver Dam Eye Study. Arch Ophthalmol. 2001;119:246-250.
13. Delcourt C, Michel F, Colvez A, Lacroux A, Delage M, Vernet MH. Associations of cardiovascular disease and its risk factors with age-related macular degeneration: The POLA Study. Ophthalmic Epidemiol. 2001;8:237-249.
14. Wachter A, Sun Y, Dasch B, Krause K, Pauleikhoff D, Hense HW. Munster age and retina study (MARS). Association between risk factors for arteriosclerosis and age-related macular degeneration. Ophthalmologe. 2004;101:50-53.
15. BeldaSanchisJI,Quijada GonzalezA,MunozRuizG,Rodriguez Galietero A, Romero Gomez FJ, Diaz Llopis M. Are blood lipids a risk factor for age-related macular degeneration? Arch Soc Esp Oftalmol. 2001;76:13-17.
16. Genest JJ, McNamara JR, Salem DN, Schaefer EJ. Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol 1991;67:1185-1189.
17. Clinical Practice Recommendations 2005. Diabetes Care 2005;28(Suppl 1):S1-79.
18. Tomany SC, Wang JJ, Van Leeuwen R, et al. Risk factors for incident age-related macular degeneration: Pooled findings from 3 continents. Ophthalmology. 2004;111:1280-1287.
19. Miyazaki M, Kiyohara Y, Yoshida A, Iida M, Nose Y, Ishibashi T. The 5-year incidence and risk factors for age-related macu-lopathy in a general Japanese population: The Hisayama Study. Invest Ophthalmol Vis Sci. 2005;46:1907-1910.
20. Hennekens CH. Current perspectives on lipid lowering with statins to decrease risk of cardiovascular disease. Clin Cardiol 2001;24:Ii-2-5.
21. Miller LJ, Chacko R. The role of cholesterol and statins in Alzheimer's disease. Ann Pharmacother. 2004;38:91-98.
22. Bauer DC, Mundy GR, Jamal SA, et al. Use of statins and fracture: Results of four prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med. 2004;164:146-152.
23. Werner N, Nickenig G, Laufs U. Pleiotropic effects of HMG-CoA reductase inhibitors. Basic Res Cardiol. 2002;97:105-116.
24. Curcio CA, Millican CL, Bailey T, Kruth HS. Accumulation of cholesterol with age in human Bruch's membrane. Invest Ophthalmol Vis Sci. 2001;42:265-274.
25. Malek G, Li CM, Guidry C, Medeiros NE, Curcio CA. Apolipoprotein B in cholesterol-containing drusen and basal deposits of human eyes with age-related maculopathy. Am J Pathol. 2003;162:413-425.
26. Hall NF, Gale CR, Syddall H, Phillips DI, Martyn CN. Risk of macular degeneration in users of statins: Cross-sectional study. Br Med J. 2001;323:375-376.
27. McGwin Jr G, Xie A, Owsley C. The use of cholesterol-lowering medications and age-related macular degeneration. Ophthalmology. 2005;112:488-494.
28. McGwin Jr G, Owsley C, Curcio CA, Crain RJ. The association between statin use and age-related maculopathy. Br J Ophthalmol. 2003;87:1121-1125.
29. McCarty CA, Mukesh BN, Guymer RH, Baird PN, Taylor HR. Cholesterol-lowering medications reduce the risk of age-related maculopathy progression. Med J Aust. 2001;175:340.
30. Wilson HL, Schwartz DM, Bhatt HR, McCulloch CE, Duncan JL. Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration. Am J Ophthalmol. 2004;137:615-624.
31. Klein R, Klein BE, Tomany SC, Danforth LG, Cruickshanks KJ. Relation of statin use to the 5-year incidence and progression of age-related maculopathy. Arch Ophthalmol. 2003;121:1151-1155.
32. van Leeuwen R, Vingerling JR, Hofman A, de Jong PT, Stricker BH. Cholesterol lowering drugs and risk of age related maculopathy: Prospective cohort study with cumulative exposure measurement. Br Med J. 2003;326:255-256.
33. Smeeth L, Cook C, Chakravarthy U, Hubbard R, Fletcher AE. A case control study of age related macular degeneration and use of statins. Br J Ophthalmol. 2005;89:1171-1175.
34. Hogg RE, Woodside JV, Gilchrist SE, et al. Cardiovascular disease and hypertension are strong risk factors for choroidal neovascularization. Ophthalmology. 2008;115:1046-1052.
35. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One-year results of two randomized clinical trials - TAP Report. Arch Ophthalmol. 1999;117:1329-1345.
36. Barbazetto I, Burdan A, Bressler NM, et al. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: Fluorescein angiographic guidelines for evaluation and treatment - TAP and VIP Report No. 2. Arch Ophthalmol. 2003;121:1253-1268.
37. Rennert G, Peterburg Y. Prevalence of selected chronic diseases in Israel. Isr Med Assoc J. 2001;3:404-408.
38. van Leeuwen R, Tomany SC, Wang JJ, et al. Is medication use associated with the incidence of early age-related maculopathy? Pooled findings from three continents. Ophthalmology. 2004;111:1169-1175.